A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Titre officiel

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

Sommaire:

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.

Description de l'essai

Primary Outcome:

  • Radiographic Progression-Free Survival (rPFS) Assessed by Investigator
Secondary Outcome:
  • rPFS Assessed by Blinded Independent Central Review (BICR)
  • Castration-resistant Prostate Cancer (CRPC)-free Survival
  • Overall Survival (OS)
  • Time to Pain Progression
  • Time to Deterioration in Health-Related Quality of Life (HRQoL)
  • Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer